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Small vessel vasculitisAbstract Aim of the work: The aim was to investigate the role of the human leukocyte antigen
(HLA) class II alleles in the development of hepatitis C virus (HCV)-related vasculitis.
Patients and methods: Fifty HCV related vasculitis patients (32 females) with a mean age of
46.78 ± 10.17 years (range 23–74 years) and a control group including 30 age and sex matched
HCV infected patients without any extra-hepatic autoimmune manifestations were recruited in this
study. Patients with vasculitis were classified into small and medium sized vessel vasculitis according
to the type of clinical manifestations. Assessment of HLA class II alleles in leukocytes of peripheral
blood of all patients and controls was performed at allele level 4 digit high resolution for DRB1
region.
Results: Seventeen patients had medium sized vessel vasculitis (group A) and 33 patients had
small sized vessel vasculitis (group B). The development of HCV-related medium sized vessel vas-
culitis is associated with HLADRB1*3 of the 1st allele and HLADRB1*1301 of the 2nd allele-
suballele, and the development of small sized vessel vasculitis is associated with HLADRB1*701
of the 1st allele-suballele.
Conclusion: The results suggest that the development and the type of HCV-related vasculitis can
be affected by the host genetic factors.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatitis C virus (HCV) is a globally prevalent pathogen and a
leading cause of death and morbidity [1]. Globally the preva-
lence and the number of people with anti-HCV has increased
308 A.A. Shahin et al.from 2.3% to 2.8% and >122 million to >185 million
between 1990 and 2005 [2]. In Egypt, the epidemiological situ-
ation differs from western countries. HCV prevalence among
the general population of Egypt is documented to be very high.
The 2008- Egypt Demographic and Health Survey (EDHS)
reported the HCV prevalence to be 14.7% among a nationally
representative sample of 11,126 Egyptians aged 15–59 years
[3]. This prevalence appears to increase dramatically with age
with the highest rates observed among populations older than
40 years [4].
Chronic HCV infection is associated with multiple extra-
hepatic manifestations (EHM) affecting various organs in the
body. Approximately 40% to 75% of patients with chronic
HCV infection experience at least one clinical EHM during
the course of the HCV infection [5]. Many of these EHM are
autoimmune in nature due to the lymphotropism of the virus.
Mixed Cryoglobulinemia (MC) is the most documented disor-
der among them. The prevalence of HCV-infected patients
with coexisting circulating MC (reversibly cold precipitable
immunoglobulins) ranging from less than 10% to greater than
50%; however, overt vasculitis manifestations are seen in only
2–3% of these patients [6].
Gene polymorphisms of various cytokines and biomarkers
have been implicated in the susceptibility of rheumatic diseases
as rheumatoid arthritis (RA) [7–11] and systemic lupus erythe-
matosus (SLE) [11–13] in Egyptian patients, some of which
were related to the degree of activity. Interestingly, other gene
polymorphisms were not found to contribute to the develop-
ment of RA in an Argentinean cohort [14], to the risk of arthri-
tis in Turkish psoriatic patients [15] or to the development of
SLE in Egyptian patients [16,17].
The human leukocyte antigen (HLA) genomic region at
chromosomal position 6p21 encodes many genes, which are
important for the immune system [18]. Previous studies have
shown that polymorphisms in the classical class-I and -II
regions were associated with chronic hepatitis C [19,20]. In
addition, expression of HLA class I and II antigens has been
shown to affect the susceptibility and persistence of viral infec-
tion, and influence the disease progression in patients with
viral hepatitis B or C [21].
The aim of the study was to investigate the HLA class II
polymorphisms among chronic HCV infected patients with
and without vasculitis, and to study its relation to the clinical
manifestations throughout the course of the disease.2. Patients and methods
This cross sectional study included 50 consecutive patients
with HCV vasculitis (32 women with male to female ratio
0.56, 23–74 year old with mean age 46.78 ± 10.17 years) and
30 consecutive patients with HCV with no extrahepatic mani-
festations as controls (14 women with male to female ratio
1.14, 31–60 year old with mean age 49.2 ± 8.02 years). They
were recruited from the clinics of Rheumatology and Endemic
Medicine, Kasr Al Ainy hospital, Cairo University, over one
year starting from March 2012. Patients were identified as
HCV-related vasculitis using the preliminary classification cri-
teria for cryoglobulinemic vasculitis proposed by de Vita et al.
[22], which are also useful for classifying cryoglobulinemic vas-culitis in patients with negative cryoglobulins by initial labora-
tory testing. The protocol of the research has been approved
by the institutional review committee of Kasr Al Ainy Hospi-
tal, Cairo University, and it conforms to the provisions of the
World Medical Association’s declaration of Helsinki.
Informed consent was obtained from all patients for all inves-
tigations and patient anonymity was preserved.
HCV infection was confirmed in all patients by HCV quan-
titation by real time Polymerase chain reaction (PCR).
The data recorded for every patient was as follows: the
presence of rheumatologic manifestations, including arthral-
gia; arthritis; myalgia; sicca manifestations; skin manifesta-
tions (Raynaud’s phenomenon, purpura, distal ulcers,
gangrene); neurological (peripheral and/or central nervous sys-
tem (CNS) manifestations, including impaired cognitive func-
tion and abnormal findings on magnetic resonance imaging
of the brain); cardiac; pulmonary; renal; gastrointestinal (pep-
tic ulcers, mesenteric microaneurysms); hepatic; or ophthalmo-
logic involvement. The laboratory data included the
rheumatoid factor (RF), antinuclear antibodies (ANA), and
anti-double stranded nucleic acid (anti-DNA) antibodies, if
ANA was positive. Antineutrophil cytoplasmic antibodies
(ANCA), cryoglobulins, and complement components C3
and C4 were done for all patients.
Patients were divided into two groups according to the
revised International Chapel Hill Consensus Conference
Nomenclature of Vasculitides [23] into patients with
medium-vessel vasculitis and with small-vessel vasculitis.
Exclusion criteria included: (1) Patients with coexistent
Hepatitis B virus (HBV); by performing HB surface Antigen
(HBsAg) and Hb core Antibody (HBcAb) using Enzyme
linked immunosorbent essay (ELISA) technique. (2) Human
immunodeficiency virus (HIV); by performing HIV I and
HIV II antibody testing by ELISA. (3) Co-existence of autoim-
mune, proliferative, or other infectious disease except HCV
infection. (4) The presence of other causes of vasculitis.
Assessment of HLA class II alleles in leukocytes of periph-
eral blood was performed at allele level 4 digit high resolution
for DRB1 region using LABType SSO Typing Test, which
applies LuminexTM technology for DNA typing as recom-
mended by Luminex Corporation [24]. Measurements were
achieved using Luminex 100TM device at Clinilab Company
(Egypt). The overall method of HLA genotyping included
PCR amplification, denaturation, neutralization, hybridiza-
tion, streptavidine-phycoerythrine reaction and measurements.
Upon HLA typing to the patients, and controls, we detected
the 1st and 2nd alleles, in addition to the suballeles of the
1st and 2nd alleles, from which we have selected the 1st 2 num-
bers to display.
Statistical methods: All patients’ data were tabulated, and
processed using Statistical package for sciences and society
(SPSS 11.0) (SPSS Inc., Chicago, USA). Quantitative variables
were expressed by mean and standard deviation (SD) and then
compared using Student’s t-test for two independent variables.
We expressed Qualitative variables by frequency and percent-
age and compared them using chi-square test or Fischer’s exact
test. Odds ratio (OR) and their 95% confidence interval (CI)
were calculated for the presence of each HLA class II alleles
in patients and controls. P value was considered significant if
equal or less than 0.05.
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Our HCV-vasculitis group was formed of 32/50 (64%) females,
with male to female ratio 0.56. Their ages ranged from 23 to
74 years with a mean of 46.78 ± 10.17 years, with male to
female ratio 0.56. The duration of HCV diagnosis ranged from
2 months to 14 years with mean 3.04 ± 3.28 years, whereas,
the duration of vasculitis ranged from 3 months to 12 years
with a mean of 2.61 ± 3.01 years. The clinical characteristics
are shown in Table 1. All HCV-vasculitis patients were nega-
tive for anti-DNA and ANCA. On the other hand, among
the 30 control subjects, 14 were females (46.7%), with male
to female ratio 1.14. Their ages ranged from 31 to 60 years
with a mean of 49.2 ± 8.02 years. The duration of HCV in this
group ranged from 5 months to 15 years with a mean of 4.21
± 3.98 years. The difference between patients and controls
concerning age, sex and disease duration was non-significant.
Patients were classified into two groups according to the
size of the vessel involved: group A; patients with medium ves-
sel vasculitis (17 patients), and group B; patients with small-
vessel vasculitis (33 patients).
On analyzing each of the 1st and the 2nd HLA class II alle-
les, and comparing HCV-controls to all HCV-vasculitis
patients, group A and group B; DRB1*3 on the 1st allele
was detected significantly more frequently in group A com-
pared to the HCV-controls (p = 0.027), and HLA DRB1*4
on the 1st allele was detected significantly more frequently in
the HCV-control group (p = 0.05) (Table 2).
HLA DRB1*15 on the 2nd allele was detected significantly
more in the HCV-control group (p = 0.048) compared to all
HCV-vasculitis patients (Table 3).
We have chosen from the vast sequence of suballeles the
1stsuballele (the 1st 2 digits). The 1st allele-suballele
DRB1*701 was significantly more frequently detected in group
B when compared to the HCV-control group (p = 0.05). The
most frequent 1st allele-suballeles detected in patient and con-
trol population are shown in Table 4.Table 1 Clinical and laboratory characteristics of the HCV-
vasculitis group.
Characteristic n (%) HCV-vasculitis patients (n= 50)
Fever 7 (14)
Fatigue 10 (20)
Fibromyalgia 6 (12)
Arthralgia 26 (52)
Arthritis 11 (22)
Purpura 28 (56)
Skin ulcers 6 (12)
Digital gangrene 9 (18)
Livedo reticularis 1 (2)
Raynaud’s phenomenon 5 (10)
Cranial nerve involvement 4 (8)
Peripheral neuropathy 18 (36)
Low C4 17 (34)
Low C3 12 (24)
Positive RF 43 (86)
Positive cryoglobulins 15 (30)
Positive ANA 13 (26)
HCV: hepatitis C virus, C: complement, RF: rheumatoid factor,
ANA: antinuclear antibody.Similarly, we compared the frequency of the 1stsuballele
(1st 2 digits) of the 2nd allele among HCV patient with and
without vasculitis. The 2nd allele-suballele DRB1*1301 was
significantly detected more in group A when compared to
the HCV-control group (p = 0.05) (Table 5).
No significant relation was found between the distribution
of the different alleles and the clinical manifestations of
patients with vasculitis except for the prevalence of mononeu-
ritis multiplex, which was present in 10 patients (9 of them
were in group A) and none of them had DRB1*4 on the 1st
allele (x2 = 0.06). They had different alleles including; DR
B1*1,*3,*7,*10,*11,*13,*14. DRB1*4 was present in 11 HCV
vasculitis patients, none of them had mononeuritis multiplex.
4. Discussion
Although the pathogenic basis for the development of HCV
related vasculitis is not fully understood, it is clear that it is
complex and multifactorial. Many factors have been postu-
lated for the development of MC, such as the virus genotype.
For example, the prevalence of MC in Egyptian patients
infected with HCV-genotype 4 was 14%, and that was signifi-
cantly lower than its prevalence in Japanese patients infected
with genotype 1b (40%) [25].
Other studies suggest that not only the genotype of the
virus affects the disease, but it is believed that HCV is able
to trigger such a disorder only in the presence of genetic factors
that are yet to be identified. The host’s genetic background
forms a complex relationship with HCV thus leading to devel-
opment of the disease and perhaps leads to different patterns
of presentation. Some of these genetic factors include HLA
polymorphisms (as HLA-A9, HLA-B8-DR3, HLA-DR3, and
HLA-DR5-DQ3) [26–29].
We aimed in this work to study HLA class II alleles in
leukocytes of peripheral blood, which are the commonest alle-
les found in those patients, and to study its relation to the clin-
ical manifestations throughout the course of the disease. We
studied it at allele level 4 digit high resolution for DRB1
region.
On comparing the HCV control group to the group of
patients with HCV vasculitis, we failed to correlate the HCV
vasculitis to a specific gene in our patients, but we found that
HLADRB1*15 of the 2nd allele was statistically higher in the
control group (p= 0.048, OR = 4.18, [95%CI1.14-15.4]).
This can suggest it as a protective gene in our study
population.
Two main forms of vasculitis have been identified in rela-
tion to the chronic HCV infection; the more common cryo-
globulinemic vasculitis, which is a chronic small vessel
vasculitis, and the less common polyarteritis nodosa like vas-
culitis, which is a medium vessel vasculitis occurs in the setting
of the chronic HCV infection [30].
We subdivided the HCV vasculitis patients into 2 groups
according to the type of the vessel involved (group A; medium
size vessel and group B; small size vessel). HLADRB1*3 of the
1st allele was statistically significantly more frequent in group
A when compared to the control group (p = 0.027,
OR= 0.23, [95% CI 0.06–0.87]). HLADRB1*1301 of the
2nd allele-suballele was statistically significantly higher in
group A when compared to the control group (p = 0.05,
OR= 0.11, [95% CI 0.01–1.1), while HLADRB1*4 of the
Table 2 Comparison of the 1st allele prevalence between HCV-controls with the HCV-vasculitis patients, patients with medium-sized
(group A) and small-sized (group B) vasculitis.
1st allele HCV patients HCV-vasculitis (vessel size)
Control (n= 30) Vasculitis (n= 50) Medium-sized (n= 17) Small-sized (n= 33)
n (%) n (%) p OR 95% (CI) n (%) p OR 95% (CI) n (%) p OR 95% (CI)
DRB1*1 4 (13.3) 5 (10) 0.72 1.39 (0.34–5.62) 1 (5.9) 0.64 2.46 (0.25–24.02) 4 (12.1) 1 1.12 (0.25–4.92)
DRB1*3 5 (16.7) 14 (28) 0.29 0.51 (0.16–1.61) 8 (47.1) 0.027 0.23 (0.06–0.87) 6 (18.2) 1 0.9 (0.24–3.32)
DRB1*4 9 (30) 11 (22) 0.6 1.52 (0.54–4.25) 1 (5.9) 0.05 6.86 (0.79–59.81) 10 (30.3) 1 0.99 (0.34–2.99)
DRB1*7 4 (13.3) 8 (16) 1 0.81 (0.22–2.95) 3 (17.6) 1 0.72 (0.14–3.67) 5 (15.2) 1 0.86 (0.21–3.56)
DRB1*13 2 (6.7) 7 (14) 0.47 0.44 (0.09–2.29) 2 (11.8) 0.61 0.54 (0.07–4.19) 5 (15.2) 0.43 0.4 (0.07–2.24)
Bold values are significant at p 6 0.05, OR; Odds Ratio, CI; confidence interval.
Table 3 Comparison of the 2nd allele prevalence between HCV-controls with the HCV-vasculitis patients, patients with medium-
sized (group A) and small-sized (group B) vasculitis.
2nd allele HCV patients HCV-vasculitis (vessel size)
Control (n= 30) Vasculitis (n= 50) Medium-sized (n= 17) Small-sized (n= 33)
n (%) n (%) p OR 95% (CI) n (%) P OR 95% (CI) n (%) p OR 95% (CI)
DRB1*4 4 (13.3) 10 (20) 0.55 0.62 (0.18–2.17) 4 (23.5) 0.44 0.5 (0.11–2.33) 6 (18.2) 0.74 0.69 (0.18–2.74)
DRB1*13 7 (23.3) 16 (32) 0.46 0.65 (0.23–1.82) 5 (29.4) 0.73 2.73 (0.19–2.8) 11 (33.3) 0.15 0.7 (0.31–1.57)
DRB1*14 5 (16.7) 10 (20) 0.78 0.8 (0.25–2.61) 4 (23.5) 0.7 0.65 (0.15–2.84) 6 (18.2) 0.42 0.61 (0.2–1.85)
DRB1*15 8 (26.6) 4 (8) 0.048 4.18 (1.14–15.4) 1 (5.9) 0.13 5.82 (0.66–51.28) 3 (9.1) 0.1 3.64 (0.87–15.29)
Bold values are significant at p 6 0.05, OR: Odds Ratio, CI: confidence interval.
Table 4 Comparison of the 1st allele-suballele prevalence between HCV-controls with the HCV-vasculitis patients, patients with
medium-sized (group A) and small-sized (group B) vasculitis.
1stallele-Suballele HCV patients HCV-vasculitis (vessel size)
Control (n= 30) Vasculitis (n= 50) Medium-sized (n= 17) Small-sized (n= 33)
n (%) n (%) p OR 95% (CI) n (%) P OR 95% (CI) n (%) p OR 95% (CI)
DRB1*102 5 (16.7) 4 (8) 0.28 2.3 (0.57–9.35) 1 (5.9) 0.4 3.2 (0.34–29.96) 3 (9.1) 0.46 2.0 (0.44–9.21)
DRB1*301 4 (13.3) 10 (20) 0.55 0.62 (0.18–2.17) 1 (5.9) 0.64 2.46 (0.25–24.02) 7 (21.2) 0.52 0.57 (0.15–2.19)
DRB1*402 4 (13.3) 7 (14) 1 0.95 (0.25–3.54) 1 (5.9) 0.64 2.46 (0.25–24.02) 6 (18.2) 0.74 0.69 (0.18–2.74)
DRB1*701 1 (3.3) 8 (16) 0.14 0.18 (0.02–1.53) 1 (5.9) 1 0.55 (0.03–9.43) 7 (21.2) 0.05 0.13 (0.02–1.11)
Bold values are significant at p 6 0.05, OR: Odds Ratio, CI: confidence interval.
Table 5 Comparison of the 2nd allele-suballele prevalence between HCV-controls with the HCV-vasculitis patients, patients with
medium-sized (group A) and small-sized (group B) vasculitis.
1stallele-Suballele HCV patients HCV-vasculitis (vessel size)
Control (n= 30) Vasculitis (n= 50) Medium-sized (n= 17) Small-sized (n= 33)
n (%) n (%) p OR 95% (CI) n (%) P OR 95% (CI) n (%) p OR 95% (CI)
DRB1*404 1 (3.3) 4 (8) 0.65 0.4 (0.04–3.73) 3 (17.6) 0.11 0.19 (0.02–1.68) 1 (3) 1 1.1 (0.07–18.46)
DRB1*1301 1 (3.3) 7 (14) 0.25 0.21 (0.03–1.81) 4 (23.5) 0.05 0.11 (0.01–1.1) 3 (9.1) 0.61 0.35 (0.03–3.51)
DRB1*1302 2 (6.7) 6 (12) 0.7 0.52 (0.1–2.78) 3 (17.6) 0.34 0.33 (0.05–2.23) 3 (9.1) 1 0.71 (0.11–4.6)
DRB1*1401 4 (13.3) 7 (14) 1 0.95 (0.25–3.54) 1 (5.9) 0.64 2.46 (0.25–24.02) 6 (18.2) 0.74 0.69 (0.18-2.74)
Bold values are significant at p 6 0.05, OR: Odds Ratio, CI: confidence interval.
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when compared to group A (p = 0.05, OR= 6.86, [95% CI
0.79–59.81]). Although the p value was significant, their CI
was not pre´cised.
HLADRB1*701 of the 1st allele-suballele was statistically
significantly higher in group B when compared to control
group (p = 0.05, OR = 0.13 [95% CI 0.02–1.11]). The CI
was not pre´cised, but still the p value was significant.
This is the first study to our knowledge that suggests a
genetic basis for the different forms of the HCV associated vas-
culitis, either medium or small vessel affected presentations.
In conclusion, the results suggest that the development of
HCV-related medium sized vessel vasculitis is associated with
HLADRB1*3 of the 1st allele and HLADRB1*1301 of the
2nd allele-suballele, and the development of small sized vessel
vasculitis is associated with HLADRB1*701 of the 1st allele-
suballele. HLADRB1*15 of the 2nd allele may be protective
against the development of vasculitis in HCV patients.
HLADRB1*4 of the 1st allele was absent in patients with
mononeuritis multiplex. A bigger study is recommended to
verify these findings.Conflict of interest
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